RBC Capital Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $112.3
Alcon (ALC) Gets a Buy From RBC Capital
Deutsche Bank Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $103.26
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $111.63
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alcon (ALC) and Cooper Co (COO)
J.P. Morgan Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $105.88
Baird Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $108
Stifel Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $100
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $91.6 to $107
Baird Maintains Outperform on Alcon, Raises Price Target to $108
Analysts Conflicted on These Healthcare Names: Agilon Health (AGL), AN2 Therapeutics, Inc. (ANTX) and Alcon (ALC)
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $91.84 to $106
Alcon Analyst Ratings
Alcon's Strong Q4 Performance and Market Share Gains Reinforce Buy Rating Despite Lower 2025 Guidance
Stifel Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $100
Alcon (ALC) Receives a Hold From Kepler Capital
Wells Fargo Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $105
Alcon Is Maintained at Overweight by Keybanc
Alcon Analyst Ratings
Needham Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $106